CLAIM AMENDMENTS

- 1.-79. (cancelled)
- 80. (previously presented) An isolated ELR-CXC chemokine antagonist, consisting of the amino acid sequence set forth in SEQ ID NO:1.
- 81. (currently amended) An isolated ELR-CXC chemokine antagonist having comprising the amino acid sequence as set forth in SEQ ID No. 1 but wherein amino acid 30 of SEQ ID NO:1 is Gly instead of Pro and amino acid 29 of SEQ ID NO: 1 is glycine instead of proline.
- 82. (currently amended) An isolated ELR-CXC chemokine antagonist havingcomprising the amino acid sequence as set forth in SEQ ID No. 1 but wherein amino acid 10 of SEQ ID NO:1 is Ser instead of Thr and amino acid 11 of SEQ ID NO: 1 is Phe instead of His.
- 83. (currently amended) An isolated ELR-CXC chemokine antagonist havingcomprising the amino acid sequence as set forth in SEQ ID No. 1 but wherein amino acid 11 of SEQ ID NO:1 is Phe Instead of His, amino acid 10 of SEQ ID NO:1 is Ser instead of Thr. amino acid 30 of SEQ ID NO:1 is Gly instead of Pro and amino acid 29 of SEQ ID NO:1 is glycine instead of proline.
- 84. (previously presented) A method for treating an ELR-CXC chemokine-mediated pathology, said pathology selected from the group consisting of ischemia-reperfusion injury, acute respiratory distress syndrome, immune complex-type glomerulonephritis, bacterial pneumonia and mastis, in which an ELR-CXC chemokine binds to CXCR1 or CXCR2 receptors in a mammal, the method comprising administering to said mammal an effective amount of the ELR-CXC chemokine antagonist as recited in claim 80.
 - 85, cancelled
- 86. (previously presented) The method of claim 84, wherein the pathology is acute respiratory distress syndrome.